<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03145064</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-207</org_study_id>
    <nct_id>NCT03145064</nct_id>
  </id_info>
  <brief_title>Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Screening (up to 28 days); daily treatment until disease progression, unacceptable toxicity
      or death, withdrawal of consent, lost to follow-up, or study termination from sponsor;
      treatment (up to 2 years), safety follow up (28 days); survival follow-up until data cutoff
      for final analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an single-arm, multicenter, open-label Phase 2 study to evaluate efficacy, safety,
      tolerability of BGB-3111 in subjects with relapsed/refractory non-GCB type Diffuse Large B
      Cell Lymphoma.

      The study is composed of two cohorts. Cohort 1 will be approximately 70 subjects and Cohort 2
      will be approximately 30 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of objective response</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The achievement of either a partial response (PR) or complete response (CR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Defined as time from first dose of BGB-3111 until first documentation of Progression (by IWG on NHL criteria) or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Defined as the time from the date that the response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Defined as the time from first dose of BGB-3111 to documentation of a response.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Defined as the time from first dose of BGB-3111 until death.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort1,Cohort2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>BGB-3111 at a dose of 160 mg orally (PO) twice daily (BID)</description>
    <arm_group_label>Cohort1,Cohort2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed non-germinal center diffuse large B cell lymphoma (DLBCL), by
             immunohistochemistry using the Hans algorithm,

               1. CD10- and BCL6-,

               2. CD10-, BCL6+, but MUM1+

          2. Men and women ≥ 18 years of age.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          4. Measurable disease is defined as at least 1 lymph node &gt;1.5 cm in longest diameter and
             measurable in 2 perpendicular dimensions.

          5. All subjects must provide fresh tumor biopsy or recent tumor tissue samples (in one
             year). Cohort 2 subjects must provide fresh tumor biopsy at screening and Cycle 1 Day
             3.

          6. Received at least one prior therapy for DLBCL that includes anthracycline based
             chemotherapy.

          7. Patient not eligible for or refuses intensive chemotherapy and hematopoietic stem cell
             transplant.

          8. Documented failure to achieve at least partial response (PR) with, or documented
             disease progression after response to, the most recent treatment regimen.

          9. Neutrophils ≥ 1 x 109/L independent of growth factor support within 7 days of study
             entry.

         10. Platelets ≥ 75 x 109/L, independent of growth factor support or transfusion within 7
             days of study entry

         11. Creatinine clearance of ≥ 30 mL/min (as estimated by the Cockcroft-Gault equation or
             estimated glomerular filtration rate [eGFR].

         12. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN.

         13. Bilirubin ≤ 2 x ULN (unless documented Gilbert's syndrome), then up to 5xULN allowed.

         14. Hemoglobin ≥ 8 g/dL.

         15. International normalized ratio (INR) ≤ 1.5 and activated partial thromboplastin time
             (APTT) ≤ 1.5 x ULN.

         16. Subjects may be enrolled who relapse after autologous stem cell transplant if they are
             at least 6 months after transplant, subjects should have no active infections (ie,
             fungal or viral).

         17. Females of childbearing potential must agree to use highly effective forms of birth
             control throughout the course of the study and at least up to 90 days after last dose
             of study drug. Highly effective forms of birth control can be defined as abstinence,
             hysterectomy, bilateral oophorectomy with no menstrual bleeding for up to 6 months,
             intrauterine contraception, hormonal methods such as contraceptive injection, oral
             contraceptive, etc. Males must have undergone sterilization-vasectomy, or utilize a
             barrier method where the female partner utilizes the effective forms of birth control
             noted above.

         18. Life expectancy of &gt; 3 months.

         19. Able to provide written informed consent and can understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          1. Current or history of central nervous system (CNS) lymphoma.

          2. Prior exposure to a BTK inhibitor.

          3. Prior corticosteroids (at dosages equivalent to prednisone &gt; 20 mg/day) given with
             anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, or
             radiation therapy within 3 weeks, or antibody based therapies or Chinese anti-cancer
             herbal therapies within 4 weeks of the start of study drug.

          4. Major surgery within 4 weeks of screening.

          5. Toxicity of ≥ Grade 2 from prior anti-cancer therapy (except for alopecia, absolute
             neutrophil count (ANC) and platelets. For ANC and platelets, please follow inclusion
             criteria #9 [neutrophils] and #10 [platelets]).

          6. History of other active malignancies within 2 years of study entry, with exception of
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally
             (surgery or other modality) with curative intent.

          7. Currently active clinically significant cardiovascular disease such as uncontrolled
             arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by
             the New York Heart Association (NYHA) Functional Classification, or history of
             myocardial infarction within 6 months of screening. Left Ventricular Ejection Fraction
             (LVEF) is lower than 50% measured by echocardiography (ECHO) (AHA,2016).

          8. QTcF (Fredericia's correction) &gt; 450 msecs or other significant ECG abnormalities
             including second degree atrioventricular (AV) block Type II, or third degree AV block.

          9. Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

         10. Uncontrolled systemic infection or infection requiring parenteral anti-microbial
             therapy.

         11. Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
             infection (detected positive by polymerase chain reaction [PCR]).

         12. Pregnant or lactating women.

         13. Any life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, or put the study at
             risk.

         14. On medications which are strong cytochrome P450, family 3, subfamily A (CYP3A)
             inhibitors or CYP3A inducers, or Chinese herbal medications, unless absolutely
             essential for patient wellbeing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male and female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liudi Yang</last_name>
    <phone>+86 10 589580000</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Chengdu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhengjiang Cancer hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Hangzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Suzhou</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute&amp;Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2017</study_first_submitted>
  <study_first_submitted_qc>May 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsed/refractory non-GCB type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

